Honz charges Johnson&Johnson's of unfair competition

Hainan Honz Pharmaceutical Co., Ltd., is accusing Johnson&Johnson's of unfair competition by spreading false information to misled consumers. Honz said to reserve the right to take legal actions to rumor mongers.
Honz said that false information of Honz's product, Nimesulide, an antipyretic medicine, is harmful to the livers and kidneys and is not allowed for infant use in other countries, was released on an industry conference in November 2010 sponsored by Johnson&Johnson's, domestic media the China Business News said Monday. Johnson&Johnson's warned major hospitals of the rumors and put the information on its website.
Honz guarantees the safety of its products, citing researches by the State Food and Drug Administration (SFDA) and local branches of SFDA in Guangdong Province, which tested them unharmful.
Lv Jing, Johnson&Johnson's public relations official, could not be reached when contacted by the Global Times.
Li Youquan, secretary of the board of directors told the Global Times that the product is very safe, and calls the move by Johnson&Johnson's unfair competition.
Nimesulide is Honz's most popular product, accounting for 80 percent of its total sales. Due to the rumors, the company halted its stock tradings on Feburary 14, 2011 and filed an announcement saying the information blemishing Nimesulide's image is unfounded. But despite of doing so, Honz's business is still seriously affected, and many drug stores have suspended sales and are recalling the product.